TransCode Therapeutics, Inc. (RNAZ) Gamma Exposure (GEX) & Greeks

Gamma exposure (GEX) analysis shows how options positioning creates dealer hedging pressure across strikes. Includes delta, vanna, charm, vomma, and vega exposure by strike price.

TransCode Therapeutics, Inc. (RNAZ) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $4.8M, listed on NASDAQ, employing roughly 7 people, carrying a beta of 1.40 to the broader market. TransCode Therapeutics, Inc. Led by Philippe Calais, public since 2021-07-08.

Greeks exposure analysis shows dealer hedging pressure across strike prices for all six Greeks. No recent options activity for RNAZ as of 2026-06-01; this typically reflects low options liquidity, a recently listed name, or a temporary data feed delay. Snapshot will refresh on the next active session.

Learn how gamma exposure is reported and how to read the data →